Detalhe da pesquisa
1.
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Nature
; 629(8013): 927-936, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588697
2.
An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies.
Gastroenterology
; 166(2): 298-312.e14, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37913894
3.
"Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug".
bioRxiv
; 2024 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38746175
4.
Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression.
Cancer Discov
; 14(2): 348-361, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966260
5.
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma.
bioRxiv
; 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38105998
6.
Aberrant NFATc1 signaling counteracts TGFß-mediated growth arrest and apoptosis induction in pancreatic cancer progression.
Cell Death Dis
; 10(6): 446, 2019 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171768
7.
Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer.
Cells
; 9(1)2019 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31878349
8.
Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients.
Front Med (Lausanne)
; 5: 320, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510930